As lead has been shown to activate protein kinase C (PKC), and gliomas are reported to be highly dependent on PKC for their proliferation, this study was undertaken to investigate whether lead may act as a mitogen in human astrocytoma cells, and to determine the role of PKC in this effect. Lead acetate (from 100 nM to 100 mM) induced a concentration-and time-dependent increase in DNA synthesis, as measured by incorporation of [methyl-3 H]thymidine into cell DNA, without causing any cytotoxicity. Flow cytometric analysis showed that lead was able to stimulate the cell cycle transition from the G 0 /G 1 phase to the S/G 2 phase, resulting in increased percentage of cells in the latter phase. Western blot analyses showed that lead induced translocation of PKCa, but not of PKC1 or PKCz, from the cytosolic to the particulate fraction, with a concomitant increase in PKC enzyme activity.
example, neurotransmitter release, cell proliferation or differentiation, apoptosis, and learning and memory processes (Tanaka and Nishizuka 1994; Livneh and Fishman 1997; Van Der Zee and Douma 1997) .
The interaction of lead with conventional PKCs has received considerable attention since the ®nding that this metal can activate PKC in immature rat brain microvessels and in brain tissues, by mimicking calcium (Markovac and Goldstein 1988a; 1988b) . These ®ndings have been con®rmed by several investigators in different cell types and under different experimental conditions (Laterra et al. 1992; Long et al. 1994; Tomsig and Suszkiw 1995; Guity and Pounds 1997; Schanne et al. 1997) , though inhibitory effects of lead have also been reported (Murakami et al. 1993; Tonner and Heiman 1997) . Still, other studies have found that lead may activate or inhibit PKC depending on the concentration of free metal (Tomsig and Suszkiw 1995; Sun et al. 1999) . Activation of PKC by lead has been suggested to be involved in its inhibition of astrogliainduced microvessel formation (Laterra et al. 1992) , to contribute to its ability to release neurotransmitters from bovine adrenal chromaf®n cells and PC12 cells (Tomsig and Suszkiw 1995; Bressler et al. 1996) , and to mediate leadinduced rise in intracellular free calcium in osteoblastic bone cells (Schanne et al. 1997) .
In the present study, we investigated whether an interaction of lead with PKC may lead to an increase in cell proliferation. For this purpose, we utilized a human astrocytoma cell line, which expresses the a, 1 and z subtypes of PKC (Post et al. 1996) . Several lines of evidence indeed indicate that PKCs, and particularly PKCa, play a relevant role in the proliferation of glioma cells (Couldwell et al. 1991; Baltuch and Yong 1996) . Glioma cells display inherent high levels of PKC, particularly the a isozyme, which correlates with their growth rate (Couldwell et al. 1991) . Phorbol esters are potent mitogens in several glioma cell lines , and various PKC inhibitors, as well as an antisense oligonucleotide to PKCa, inhibit their proliferation (Ahmad et al. 1994) . A study in which much of this evidence was replicated in various glioma cell lines concluded that signal transduction for proliferation of glioma cells in vitro occurs predominantly through a PKCmediated pathway (Baltuch and Yong 1996) . Thus, astrocytoma cells represent a good model to investigate the interaction of lead and PKC in correlation with a speci®c cellular response, i.e. cell proliferation.
Materials and methods

Materials
Dulbecco's modi®ed Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin and trypsin were purchased from Gibco BRL (Grand Island, NY, USA). H]thymidine (6.7 Ci/mmol) was from NEN (Boston, MA, USA). Polyclonal antibodies to PKCa, PKC1, PKCz and the protease inhibitor cocktail were from Boehringer Mannheim (Indianapolis, IN, USA). Horseradish peroxidase-conjugated donkey anti-rabbit IgG antibody and the myristoylated PKC peptide inhibitor that is based on the pseudosubstrate region for classical PKC (Myr-Arg-PheAla-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val), were purchased from Promega (Madison, WI, USA). Lead acetate and all other chemicals were purchased from Sigma Chemical Co. (St Louis, MO, USA). Lead acetate was dissolved in deionized water and prepared as a 2-mm stock solution.
Culture of 1321N1 human astrocytoma cells
The human astrocytoma cell line 1321N1 (obtained from Dr J. H. Brown, University of California at San Diego, CA, USA) was used in all these studies. These cells were originally isolated from primary cultures of cerebral glioma multiforme, and the 1321N1 cells are a subclone isolated in 1972 from a line designated 1181N1 (Foster and Perkins 1977) . Cells were maintained in low-glucose DMEM, supplemented with 5% FBS, 1 U/mL penicillin G and 1 mg/mL streptomycin in 75 cm 2¯a sks under a humidi®ed atmosphere of 5% CO 2 /95% air at 378C. Cells were subcultured every 7 days, and the growth medium was changed every 3 or 4 days. Cells were seeded in 24-well plates at the density of 2.5 Â 10 4 /mL for the proliferation experiments, and in 100 mm dishes at the density of 1 Â 10 5 /mL for western blot experiments.
Assays of cell proliferation
Incorporation of [methyl-3 H]thymidine into cell DNA was measured as described previously . Brie¯y, cells were seeded at the density of 2.5 Â 10 4 /mL in 24-well plates. After 4 days in medium supplemented with 5% FBS, cells were switched to serum-free medium supplemented with 0.1% bovine serum albumin (BSA) for 48 h, before treatment. Treatment with lead or other compounds was for 24 h. One mCi/well of [methyl-3 H]thymidine was included for the last 6 h of the incubation at 378C under an atmosphere of 5% CO 2 /95% air. At the end of the incubation, cells were washed twice with cold PBS and ®xed in methanol. Unincorporated 3 Hthymidine was removed by two washes with ice-cold 10% trichloroacetic acid and one wash of ice-cold 0.5% trichloroacetic acid. The monolayer was dissolved in 500 mL of 1 m NaOH and 250 mL was transferred to scintillation¯uid and counted for radioactivity in a Beckman LS5000 CE scintillation counter.
Flow cytometric analysis was carried out using the doublestaining method with 5-bromodeoxyuridine (BrdU) and Hoechst 33258, developed by Rabinovitch et al. (1988) , with slight modi®cations . BrdU (150 mm) was added to the medium together with agonists. After 48 h of incubation with the agonist and BrdU, cells were harvested by trypsin and centrifuged. The pellet was resuspended in 500 mL of a solution containing 0.154 m NaCl, 0.1 m Tris (pH 7.4), 0.5 mm MgCl 2 , 0.2% BSA, 0.1% NP-40 and 5.9 mg/mL Hoechst 33258. Ethidium bromide (1.5 mg/mL) was added 15 min before the doubly stained cells (10 000 for each sample) were analyzed bȳ ow cytometry. Ultraviolet excitation was used with analysis of Hoechst 33258¯uorescence at 350 nm and ethidium bromidē uorescence above 488 nm. Hoechst¯uorescence emission was recorded at 450 nm and ethidium bromide emission was measured Lead, protein kinase C and cell proliferation 591 with a 590-nm long-pass ®lter. Data were collected and analyzed using the MPLUS AV program (Phoenix Flow Systems, San Diego, CA, USA).
Lactate dehydrogenase (LDH) release assay After treatment, the medium was collected to measure the activity of LDH using a kit from Sigma (St Louis, MO, USA). The kinetics of the reduction of pyruvate and the oxidation of NADH were evaluated as an index of LDH activity. Incubation with 0.1% Triton X-100 for 4 h was used as positive control.
Western blot analysis of PKCs
Cells were seeded on 100-mm dishes in medium containing 5% FBS, and were switched to serum-free medium when con¯uent. Treatments were done after 48 h of serum starvation. After treatment, cells were harvested in buffer containing Tris/HCl 20 mm (pH 7.4), EGTA 0.5 mm, b-mercaptoethanol 0.1% and a protease inhibitor cocktail. Cells were broken by two cycles of freezing and thawing, and the cytosolic and membrane fractions were separated by centrifugation at 100 000 g for 20 min. The supernatant was collected as cytosolic fraction. The pellet was resuspended in a buffer containing Tris/HCl 20 mm (pH 7.4), EGTA 2 mm, EDTA 10 mm, Triton-X 0.3%, b-mercaptoethanol 0.1% and protease inhibitors, shaken at 48C for 30 min, and centrifuged at 15 000 g for 10 min. The supernatant was collected as particulate fraction. To extract protein from whole cells, similar processes without ultracentrifugation were carried out. Proteins were quanti®ed using the Bradford's method, and a 5 Â sample buffer was added. After boiling for 5±10 min, samples containing 50 mg proteins were loaded on a 8% sodium dodecyl sulfate±polyacrylamide gel (SDS±PAGE). After separation, proteins were transferred to Immobilion membranes (Millipore, Bedford, MA, USA), which were incubated in the presence of polyclonal antibodies to PKCa, PKC1 or PKCz (dilution 1 : 1500) and horseradish peroxidase-conjugated secondary antibody (dilution 1 : 2000). Bands were revealed by chemiluminescent detection using the ECL kit (Amersham, Arlington Heights, IL, USA), and densitometrically quanti®ed using a Millipore Image System.
Measurement of protein kinase C activity
Activity of PKC was measured using a non-radioactive MESACUP protein kinase assay kit from PanVera (Madison, WI, USA). The kit is based on an enzyme-linked immunosorbent assay (ELISA) that utilizes a synthetic PKC peptide (RFARKGSLRQKNV) coated on microwell. The phosphorylation of the peptide was detected through incubation with a biotinylated monoclonal antibody that recognizes the phosphorylated form of the peptide and subsequent incubation with streptavidin conjugated to peroxidase. Peroxidase substrate was then added to the microwell and the intensity of the Fig. 1 (a) Quiescent cultures of 132±1N1 astrocytoma cells were exposed to different concentrations of lead (100 nM ± 100 mM) in serum-free medium for 24 h. During the last 6 h of incubation 1 mCi/ well of [methyl-3 H]thymidine was added as described in Materials and methods. Data represent the means^SEM of at least three independent determinations. *p , 0.05, compared with control group. (b) After serum deprivation, lead (5 mM) was added for the indicated time periods; after washout with PBS, cells were shifted back to serum-free medium. Data represent the means^SEM of at least three independent determinations. *p , 0.05, compared with control group. (c) LDH activity in the medium after 24 h incubation in the presence of different concentrations of lead. The maximal leakage of LDH was measured after 4 h incubation with 0.1% Triton X-100, a concentration that does not affect LDH activity. Enzymatic activity is expressed as units/L. Data represent the means^SEM of at least four independent observations. *p , 0.01, signi®cantly different from control. color was measured spectrophotometrically at 492 nm. After separating the membrane and the cytosol through ultracentrifugation, measurements were carried out according to the instruction of the kit.
Statistical analysis
Each experiment was performed at least three times. All statistical tests were carried out using the Statview 512 program (SAS Institute Inc., Cary, NC, USA) or Microsoft Excel on a Macintosh personal computer. One-way anova followed by Fisher's least signi®cant difference test were used to determine signi®cant difference between treatments.
Results
Lead induces DNA synthesis in human astrocytoma cells Exposure to lead acetate (100 nm2100 mm) resulted in concentration-and time-dependent increases in DNA synthesis in human astrocytoma cells, as assessed by 3 H-thymidine incorporation into DNA (Figs 1a and b) . The maximum increase was about 400% of basal, and occurred after 6±18 h incubation with lead. Exposure to different concentrations of lead for 24 h did not cause any apparent cytotoxicity, as evidenced by a lack of increase in LDH release in any of the lead treatment groups (Fig. 1c) .
Lead stimulates cell cycle progression
After 48 h of serum starvation (during which cells were maintained in DMEM supplemented with 0.1% BSA), cells were synchronized in the quiescent phase, as shown in Fig. 2(a) and Table 1 . Exposure to 20 mm lead for 48 h stimulated cell cycle transition from the G 0 /G 1 phase to the Lead, protein kinase C and cell proliferation 593 S/G 2 phase, resulting in an increased percentage of cells in the S/G 2 phase, and a decreased percentage of cells in the G 0 /G 1 phase (Fig. 2, Table 1 ). Similar results were observed after treatment with the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) ( Table 1) .
Effect of lead on PKC Lead (10±100 mm, 30 min) was able to cause translocation of PKCa, but not of PKC1 or PKCz, from the cytosolic to the membrane fraction in human astrocytoma cells (Fig. 3a) . On the other hand, TPA induced the translocation of both PKCa and PKC1, but not of PKCz. Treatment with lead or TPA also resulted in an increase in membrane-associated PKC activity and a corresponding decrease in cytosolic PKC activity (Fig. 3b) . Prolonged treatments with lead or TPA for 24 h or 48 h resulted in down-regulation of PKCa, as measured by western blot of whole cell-extracted protein (Fig. 4a) . PKCa was reduced to 36 (^13)% of control after 24 h incubation with lead, and 14 (^6)% of control after 24 h incubation with TPA. TPA treatment for 24 h or 48 h also down-regulated PKC1, while the effect of lead on this isozyme was not statistically signi®cant (Fig. 4b) .
PKC is involved in lead-induced DNA synthesis To determine a possible PKC involvement in the mitogenic effect of lead, two PKC inhibitors, staurosporine and GF 109203X, were tested for their ability to inhibit lead-induced DNA synthesis in human astrocytoma cells (Fig. 5a ). Both compounds inhibited the effect of lead on DNA synthesis, with IC50s of 0.41^0.08 nm and 754^120 nm for staurosporine and GF109203X, respectively (n 3). Preincubation with TPA for 24 h, which was shown earlier to down-regulate PKC (Fig. 4) , also abolished the proliferative effect of lead (Fig. 5b) .
PKCa is involved in lead-induced DNA synthesis
To further investigate the speci®c isoform of PKC involved in lead-induced DNA synthesis, we used a myristoylated PKC peptide inhibitor that is based on the pseudosubstrate region for the classical PKCs (a and b). Since 1321N1 human astrocytoma cells express only the a, 1 and z isozymes of PKC (Post et al. 1996) , the pseudosubstrate would be expected to target PKCa. Cells were pre-incubated with the pseudosubstrate (25 mm) for 45 min before treatment with lead. This pretreatment reduced PKC activity to 50±70% of control (data not shown), and blocked the ability of lead to stimulate DNA synthesis (Fig. 6a) . When cells were pre-incubated with 100 mm Pb for 24 h, a treatment which leads to selective down-regulation of PKCa (Fig. 4) , the mitogenic effect of lead was also blocked ( Fig. 6b) . Pretreatment of cells with ingenol 3, 20-dibenzoate (IDB; 50 nm for 24 h), which selectively down-regulates PKC1 without affecting PKCa (Fig. 6c,  insert) , did not affect the ability of lead to stimulate DNA synthesis. On the other hand, the mitogenic effect of the muscarinic agonist, carbachol, which has been shown to stimulate DNA synthesis through activation of PKC1 and PKCz (Guizzetti et al. 1998; Guizzetti and Costa, 2000) , was signi®cantly decreased by pretreatment with IDB (Fig. 6c) . Lead potentiates the effect of carbachol on DNA synthesis Carbachol (100 mm) alone stimulated DNA synthesis up to 500% of basal, as measured by 3 H-thymidine incorporation into DNA, con®rming previous observations (Guizzetti et al. , 1998 Guizzetti and Costa, 2000) . When cells were co-incubated with carbachol and lead, an additive or synergistic effect on proliferation was observed (Fig. 7) . Fig. 6 (a) Pre-incubation of astrocytoma cells with a pseudosubstrate to PKCa for 45 min, inhibited the effect of lead (10 mM) on DNA synthesis. *Signi®cantly different from control, p , 0.01. (b) Pre-incubation of cells with lead (100 mM, 24 h), which was shown to selectively down-regulate PKCa (Fig. 4) , inhibited the effect of lead on DNA synthesis. *p , 0.05, compared with the effect of lead in control cells. (c) Pre-incubation of astrocytoma cells with IDB (50 nM, 24 h) caused a down-regulation of PKC1, but not of PKCa (inset). Under these conditions, the ability of lead (5 mM) to stimulate DNA synthesis was not affected. On the other hand, the mitogenic effect of carbachol was signi®cantly reduced by this treatment. Data represent the means^SEM of three independent determinations. *p , 0.05, compared with the effect in control cells. incorporation by about 500%. Co-incubation with lead (5 mM), which alone caused a two-fold increase in DNA synthesis, potentiated the mitogenic effect of carbachol. Data represent the means^SEM of at least three independent determinations. *Signi®cantly different from control, p , 0.05; **Signi®cantly different from carbachol alone, p , 0.05.
Discussion
Results of this study indicate that lead acetate can stimulate DNA synthesis in human 1321N1 astrocytoma cells by a mechanism that involves activation of a classical PKC isozyme, PKCa. The mitogenic effect of lead in these cells is manifested through its ability to stimulate DNA synthesis, measured by 3 H-thymidine incorporation, and cell cycle transition, as assayed by¯ow cytometry. The effect of lead was similar to that of the phorbol ester TPA, as both compounds increased the number of cells in the S/G 2 phase to a greater extent than other mitogens such as PDGF or carbachol (Table 1 ; . TPA was, however, a more potent inducer of DNA synthesis, as indicated by a 20-fold stimulation of 3 H-thymidine incorporation , compared with 3±5-fold for lead. A signi®cant increase in DNA synthesis was observed at 5 mm lead acetate, with a maximal effect at 50 mm. None of these concentrations of lead was associated with cytotoxicity, as indicated by a lack of increase in LDH release (Fig. 1) , and by a lack of lead-induced apoptosis, as measured by DNA laddering (not shown). This con®rms the very low sensitivity of 1321N1 astrocytoma cells to lead cytotoxicity, as reported by other investigators (Mead and Pentreath 1998) .
The effect of lead on DNA synthesis was antagonized by two PKC inhibitors, GF109203X and staurosporine, and by pretreatment of cells with TPA, which caused downregulation of PKCa and 1, suggesting an involvement of PKC in the mitogenic effect of lead. Direct measurement of activation of PKC isozymes indicated that lead could stimulate translocation of the calcium-dependent PKCa, but not of PKC1 or PKCz. Prolonged incubation with lead also caused a selective down-regulation of the PKCa isozyme. Under this condition, the effect of lead on DNA synthesis was blocked. The pseudosubstrate peptide that targets PKCa also inhibited lead-induced DNA synthesis. However, when cells were pre-incubated with IDB, which selectively down-regulates PKC1, lead retained its ability to stimulate DNA synthesis. These observations indicate a primary role of PKCa in the mitogenic action of this metal in astrocytoma cells.
Lead-induced translocation of PKCa was observed at concentrations slightly higher than those required to induce DNA synthesis. For example, 10 mm lead acetate caused only a small PKCa translocation (Fig. 3) , but a three-fold increase in 3 H-thymidine incorporation into DNA (Fig. 1) . It should be noted, however, that for proliferation experiments cells were incubated with lead for 24 h, while the PKC translocation experiments were carried out after a 30-min incubation, when maximal translocation was observed. Lead has been shown to accumulate in astroglial cells, which are thought to function as a lead sink, sequestering it from the more sensitive neurons (Tiffany-Castiglioni et al. 1996) . The mechanism(s) by which lead enters astroglial cells are not fully understood, but recent evidence suggests that it may occur through l-type calcium channels (Legare et al. 1998) , with a signi®cant accumulation of lead occurring within the ®rst 24 h (Tiffany-Castiglioni et al. 1996) .
The ®nding that, of the three PKC isozymes present in human 1321N1 astrocytoma cells only the calciumdependent PKCa is activated by lead, suggests that lead may either cause an increase in intracellular calcium, or may directly activate the enzyme by mimicking calcium and binding to the C2 domain of PKC (Rizo and Su Èdhof 1998) . Indeed, lead has been shown to increase intracellular calcium levels in a number of cell types (Tiffany-Castiglioni et al. 1996) , and to substitute for calcium in activating PKC (Markovac and Goldstein 1988b) . Independently of the exact molecular mechanism, activation of PKCa by lead would represent only the ®rst step in the chain of events that leads to cell proliferation. PKCa has been shown to activate Raf-1 kinase, either by direct phosphorylation (Kolch et al. 1993) , or by modulating its membrane association (Schonwasser et al. 1998) . Raf-1, in turn, can phosphorylate MEK (MAP kinase kinase; McDonald et al. 1993) , which then activates the mitogen-activated protein (MAP) kinases ERK1 and ERK2 (Lopez-Ilasaca 1998), which play a central role in cell proliferation. In experiments to be reported elsewhere, we have indeed found that lead can activate the Raf-1/MEK/MAPK pathway in a PKCadependent manner.
Co-incubation of astrocytoma cells with lead and the muscarinic agonist carbachol provided some interesting observations with important mechanistic implications. Carbachol-induced proliferation of astrocytoma cells has been shown to involve to a small extent PKC1 and to a major degree PKCz, while PKCa seems to have a negligible role (Guizzetti et al. 1998; Guizzetti and Costa, 2000) . The additive or even synergistic effect of lead and carbachol on 3 H-thymidine incorporation, thus reinforces the hypothesis that PKCa is a primary mediator of the effect of lead on DNA synthesis.
Lead-induced increases in DNA synthesis had been previously observed following in vitro exposure, as well as after in vivo administration, but had not been investigated in relationship to PKC activation. Hitzfeld et al. (1989) found that lead increased DNA synthesis in rat kidney cells in vitro. Interestingly, the effect of lead was abolished in cells that had been`adapted' (i.e. pretreated) with lead, suggesting a possible down-regulation of PKC under this condition. Increased cell proliferation in rat kidney was also reported following in vivo administration of lead (Choie and Richter 1974) . Similarly, administration of lead nitrate to rats caused an increase of DNA synthesis in liver (LeddaColumbano et al. 1983; Liu et al. 1997) . Lead also stimulated the incorporation of [ smooth-muscle cells (Fujiwara et al. 1995) . Furthermore, lead was recently shown to stimulate proliferation of rat spleen lymphocytes in vitro (Razani-Boroujerdi et al. 1999) .
The ability of lead to stimulate DNA synthesis in human astrocytoma cells, in a manner similar to phorbol esters, may have some relevance to the potential carcinogenicity of this metal. Lead may have genotoxic properties, however, leadinduced gene mutations in mammalian cells may not be the result of direct damage to DNA, but rather, may occur by indirect mechanisms, such as inhibition of DNA repair (Zelikoff et al. 1988; Hartwig 1994) . Lead is classi®ed by IARC as a group 2B carcinogen (possible human carcinogen). In animals, there is evidence of lead inducing renal adenocarcinomas and lung adenomas in mice, and cerebral gliomas in rats (Oyasu et al. 1970; ATSDR 1999; WHO 1995) . Excess of renal (Steenland et al. 1992) , lung (Anttila et al. 1995 ) and brain (Anttila et al. 1996; Cocco et al. 1998) cancers have been found in epidemiological studies in leadexposed workers. In the study by Anttila et al. (1996) , in particular, an excess risk of gliomas (astrocytomas, glioblastoma multiform and other gliomas), was observed in workers exposed to lead, with a highly signi®cant odds ratio of 11, for a blood lead level of 1.4 mm or above. In this context, the ability of lead to stimulate DNA synthesis in astrocytoma cells by activating PKCa, may be relevant and worth further in vitro and in vivo investigations.
